Walvax Biotechnology Co (SZSE:300142) LT-Debt-to-Total-Asset : 0.03 (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Walvax Biotechnology Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Walvax Biotechnology Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.03.

Walvax Biotechnology Co's long-term debt to total assets ratio increased from Mar. 2023 (0.03) to Mar. 2024 (0.03). It may suggest that Walvax Biotechnology Co is progressively becoming more dependent on debt to grow their business.

Walvax Biotechnology Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Walvax Biotechnology Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Walvax Biotechnology Co LT-Debt-to-Total-Asset Chart

Walvax Biotechnology Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.03

Walvax Biotechnology Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.03	0.03	0.03	0.03	0.03

Walvax Biotechnology Co LT-Debt-to-Total-Asset Calculation

Walvax Biotechnology Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	455.491	/	15588.869
	=	0.03

Walvax Biotechnology Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	448.255	/	15386.882
	=	0.03

Walvax Biotechnology Co (SZSE:300142) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Walvax Biotechnology Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Walvax Biotechnology Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Walvax Biotechnology Co (SZSE:300142) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Walvax Biotechnology Co Ltd (SZSE:300142) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

Keyuan Road No. 99, 19th Floor, Building 9A, Dingyi Tiancheng Residential Quarter, High & New Tech Development Zone, Yunnan Province, Kunming, CHN, 650106

Website

http://www.walvax.com

Walvax Biotechnology Co Ltd biological pharmaceutical enterprise engaged in research and development, production and sales of bio-medicine products. It offers bio-medicines, such as vaccines, blood products, and others. The company's products include Haemophilus influenza type b conjugate vaccines, freeze-dried group A, C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines, and group A and C meningococcal polysaccharide vaccines.

Executives

Wu Yun Yan	Executives
Zhao Jin Long	Executives
Yao Wei	Executives
Zhou Hua	Executives
Shi Jing	Executives
Jiang Run Sheng	Directors, executives
Gong Sun Qing	Executives
	Executives
Yuan Lin	Executives
Fang Guo Liang	Executives
Li Yun Chun	Director
Huang Zhen	Director
Zhang Li	Secretary Dong
Yang Hong Wei	Supervisors
Xu Ke Ren	Executives

Walvax Biotechnology Co (SZSE:300142) Headlines

No Headlines